Key points from article :
Discovery of a new senolytic compound which does not use any pathways to induce apoptosis.
It is an orally bioavailable Spleen tyrosine kinase (SYK) inhibitor called R406.
SYK plays a key role in the B-cell receptor signaling pathway.
R406 reduces Immune system-mediated inflammation in early mouse, human studies.
In human trials, it was shown to inhibit activation of basophils and thus reduce inflammation.
R406 caused apoptotic cell death along with morphological changes in senescent cells (SCs).
The exact method by which R406 appears to have a senolytic effect is currently unknown.
It acts as a senolytic drug by inducing apoptosis and reducing cell attachment capacity.
It could be reducing SCs burden by improving immune system in locating and destroying them.
Published in Aging.
